Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Tuberculosis | 25 | 2021 | 2895 | 3.16 | Why? |
| Tuberculosis, Multidrug-Resistant | 8 | 2019 | 433 | 2.69 | Why? |
| Transients and Migrants | 11 | 2021 | 1468 | 2.06 | Why? |
| Antitubercular Agents | 8 | 2019 | 775 | 1.97 | Why? |
| Latent Tuberculosis | 6 | 2020 | 324 | 1.85 | Why? |
| Refugees | 9 | 2020 | 809 | 1.60 | Why? |
| Mycobacterium tuberculosis | 8 | 2020 | 1164 | 1.25 | Why? |
| Foreign Professional Personnel | 1 | 2019 | 29 | 0.78 | Why? |
| Tuberculin Test | 2 | 2017 | 141 | 0.73 | Why? |
| Extensively Drug-Resistant Tuberculosis | 2 | 2018 | 87 | 0.73 | Why? |
| Hemorrhagic Fevers, Viral | 1 | 2017 | 26 | 0.69 | Why? |
| Human Migration | 1 | 2018 | 133 | 0.67 | Why? |
| Nontuberculous Mycobacteria | 1 | 2018 | 114 | 0.66 | Why? |
| European Union | 3 | 2019 | 565 | 0.64 | Why? |
| Social Discrimination | 1 | 2020 | 269 | 0.62 | Why? |
| Mosquito Vectors | 1 | 2019 | 351 | 0.62 | Why? |
| Hemorrhagic Fever, Crimean | 1 | 2017 | 118 | 0.61 | Why? |
| Mycobacterium Infections, Nontuberculous | 1 | 2018 | 167 | 0.59 | Why? |
| Adolescent Health | 1 | 2018 | 227 | 0.58 | Why? |
| Research | 2 | 2019 | 2115 | 0.57 | Why? |
| Global Health | 10 | 2020 | 13911 | 0.56 | Why? |
| Nigeria | 8 | 2021 | 2292 | 0.56 | Why? |
| BCG Vaccine | 3 | 2020 | 1137 | 0.55 | Why? |
| Substance Abuse, Intravenous | 2 | 2017 | 411 | 0.53 | Why? |
| Health Planning | 1 | 2021 | 607 | 0.52 | Why? |
| Emigrants and Immigrants | 2 | 2018 | 888 | 0.49 | Why? |
| National Health Programs | 1 | 2019 | 807 | 0.48 | Why? |
| Hospitals, Urban | 1 | 2018 | 950 | 0.47 | Why? |
| Climate Change | 1 | 2019 | 901 | 0.43 | Why? |
| Whole Genome Sequencing | 2 | 2018 | 3239 | 0.41 | Why? |
| Racism | 2 | 2020 | 1462 | 0.40 | Why? |
| Child Health | 1 | 2018 | 940 | 0.38 | Why? |
| Rural Population | 2 | 2018 | 2408 | 0.36 | Why? |
| Health Services Accessibility | 6 | 2019 | 10697 | 0.36 | Why? |
| Vulnerable Populations | 4 | 2018 | 3099 | 0.35 | Why? |
| United Kingdom | 10 | 2021 | 18046 | 0.33 | Why? |
| Public Health | 8 | 2021 | 16359 | 0.32 | Why? |
| Interferon-gamma Release Tests | 2 | 2020 | 253 | 0.32 | Why? |
| Clinical Deterioration | 2 | 2021 | 473 | 0.31 | Why? |
| Diabetes Mellitus | 2 | 2018 | 8207 | 0.30 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.28 | Why? |
| HIV Infections | 3 | 2018 | 11620 | 0.26 | Why? |
| Myocardial Infarction | 1 | 2019 | 3361 | 0.25 | Why? |
| Northern Ireland | 3 | 2018 | 228 | 0.25 | Why? |
| Health Services | 2 | 2018 | 765 | 0.24 | Why? |
| Humans | 64 | 2021 | 930598 | 0.23 | Why? |
| Incidence | 11 | 2019 | 25622 | 0.23 | Why? |
| Minisatellite Repeats | 2 | 2018 | 53 | 0.23 | Why? |
| Health Policy | 2 | 2021 | 6242 | 0.22 | Why? |
| Wales | 3 | 2018 | 758 | 0.21 | Why? |
| Europe | 6 | 2019 | 12702 | 0.21 | Why? |
| Ethambutol | 1 | 2019 | 34 | 0.21 | Why? |
| Malaria | 2 | 2021 | 1097 | 0.21 | Why? |
| Tuberculosis, Miliary | 1 | 2021 | 66 | 0.21 | Why? |
| Pyrazinamide | 1 | 2019 | 38 | 0.20 | Why? |
| Tertiary Care Centers | 1 | 2017 | 8248 | 0.19 | Why? |
| Adolescent | 14 | 2020 | 86841 | 0.19 | Why? |
| Levofloxacin | 1 | 2019 | 115 | 0.19 | Why? |
| Monkeypox | 1 | 2018 | 40 | 0.19 | Why? |
| Urbanization | 1 | 2019 | 133 | 0.18 | Why? |
| Travel | 1 | 2017 | 7220 | 0.18 | Why? |
| Fluoroquinolones | 1 | 2019 | 235 | 0.18 | Why? |
| Molecular Typing | 2 | 2017 | 280 | 0.18 | Why? |
| Economics | 1 | 2019 | 196 | 0.17 | Why? |
| Smallpox | 1 | 2018 | 96 | 0.17 | Why? |
| Rifampin | 1 | 2019 | 276 | 0.17 | Why? |
| Bacterial Typing Techniques | 1 | 2018 | 273 | 0.16 | Why? |
| Young Adult | 13 | 2020 | 93724 | 0.16 | Why? |
| Hepatitis B Vaccines | 1 | 2019 | 245 | 0.16 | Why? |
| Risk Factors | 11 | 2020 | 71621 | 0.16 | Why? |
| Biomedical Research | 1 | 2017 | 5270 | 0.16 | Why? |
| Epidemics | 2 | 2018 | 6407 | 0.16 | Why? |
| Hepatitis C | 2 | 2017 | 1514 | 0.15 | Why? |
| Mycobacterium bovis | 1 | 2017 | 125 | 0.15 | Why? |
| Agriculture | 1 | 2019 | 367 | 0.15 | Why? |
| England | 5 | 2018 | 5116 | 0.15 | Why? |
| Anti-Bacterial Agents | 1 | 2017 | 10083 | 0.14 | Why? |
| Population Dynamics | 1 | 2018 | 378 | 0.14 | Why? |
| Armed Conflicts | 1 | 2018 | 209 | 0.14 | Why? |
| Altruism | 1 | 2018 | 300 | 0.14 | Why? |
| Conservation of Natural Resources | 1 | 2019 | 520 | 0.14 | Why? |
| London | 5 | 2021 | 2166 | 0.14 | Why? |
| Infectious Disease Medicine | 1 | 2017 | 311 | 0.14 | Why? |
| Tuberculosis, Pulmonary | 2 | 2017 | 1171 | 0.13 | Why? |
| Communicable Diseases | 2 | 2019 | 2148 | 0.13 | Why? |
| Drug Users | 1 | 2017 | 234 | 0.13 | Why? |
| Airports | 1 | 2016 | 284 | 0.13 | Why? |
| Peer Group | 1 | 2017 | 402 | 0.13 | Why? |
| Adult | 17 | 2021 | 244371 | 0.12 | Why? |
| Professional-Patient Relations | 1 | 2017 | 426 | 0.12 | Why? |
| Male | 22 | 2021 | 367725 | 0.12 | Why? |
| Program Development | 1 | 2018 | 1089 | 0.12 | Why? |
| Crowding | 1 | 2018 | 731 | 0.12 | Why? |
| Female | 22 | 2021 | 380317 | 0.12 | Why? |
| Communicable Disease Control | 2 | 2018 | 29620 | 0.11 | Why? |
| Treatment Outcome | 5 | 2018 | 51732 | 0.11 | Why? |
| Sex Distribution | 1 | 2018 | 2083 | 0.11 | Why? |
| Disease Eradication | 1 | 2017 | 581 | 0.11 | Why? |
| Human Rights | 1 | 2018 | 618 | 0.11 | Why? |
| Hepatitis B | 1 | 2019 | 888 | 0.11 | Why? |
| Middle Aged | 15 | 2021 | 270681 | 0.11 | Why? |
| Child, Preschool | 5 | 2020 | 36283 | 0.11 | Why? |
| Child | 8 | 2021 | 70012 | 0.11 | Why? |
| Models, Theoretical | 2 | 2020 | 6659 | 0.10 | Why? |
| Cohort Studies | 7 | 2020 | 36005 | 0.10 | Why? |
| Vaccination | 4 | 2020 | 19050 | 0.10 | Why? |
| Sputum | 1 | 2018 | 1720 | 0.10 | Why? |
| Cluster Analysis | 1 | 2018 | 3001 | 0.10 | Why? |
| Prevalence | 4 | 2020 | 25773 | 0.10 | Why? |
| Anti-Retroviral Agents | 1 | 2018 | 1099 | 0.10 | Why? |
| Disasters | 1 | 2018 | 760 | 0.10 | Why? |
| Retrospective Studies | 9 | 2019 | 105322 | 0.09 | Why? |
| Civil Defense | 1 | 2020 | 1687 | 0.09 | Why? |
| Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.09 | Why? |
| Mass Screening | 3 | 2019 | 8005 | 0.09 | Why? |
| Public Health Surveillance | 2 | 2019 | 3129 | 0.09 | Why? |
| Africa | 1 | 2017 | 2986 | 0.09 | Why? |
| Social Behavior | 1 | 2017 | 882 | 0.09 | Why? |
| Urban Population | 1 | 2018 | 2000 | 0.09 | Why? |
| Early Diagnosis | 2 | 2018 | 2443 | 0.09 | Why? |
| Disaster Planning | 1 | 2021 | 1680 | 0.09 | Why? |
| Aged | 12 | 2021 | 215776 | 0.09 | Why? |
| Proportional Hazards Models | 2 | 2018 | 6543 | 0.09 | Why? |
| Contact Tracing | 2 | 2021 | 8448 | 0.08 | Why? |
| Emigration and Immigration | 1 | 2012 | 501 | 0.08 | Why? |
| Databases, Factual | 2 | 2019 | 6248 | 0.08 | Why? |
| Infant | 4 | 2020 | 30274 | 0.08 | Why? |
| Delayed Diagnosis | 1 | 2017 | 1529 | 0.08 | Why? |
| Patient Care | 1 | 2018 | 1664 | 0.08 | Why? |
| Disease Outbreaks | 4 | 2018 | 27595 | 0.08 | Why? |
| Clinical Decision-Making | 1 | 2021 | 3755 | 0.08 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.08 | Why? |
| Dengue | 1 | 2019 | 1565 | 0.08 | Why? |
| Population Surveillance | 2 | 2020 | 4967 | 0.08 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.08 | Why? |
| Public Policy | 1 | 2018 | 1894 | 0.08 | Why? |
| Health Promotion | 1 | 2019 | 2020 | 0.07 | Why? |
| Health Status | 1 | 2019 | 3259 | 0.07 | Why? |
| Molecular Diagnostic Techniques | 2 | 2018 | 4239 | 0.07 | Why? |
| Zoonoses | 1 | 2018 | 3034 | 0.07 | Why? |
| Mobile Health Units | 1 | 2011 | 741 | 0.07 | Why? |
| Computer Simulation | 1 | 2019 | 4982 | 0.07 | Why? |
| Consensus | 1 | 2018 | 6345 | 0.07 | Why? |
| Risk | 1 | 2016 | 5288 | 0.06 | Why? |
| Program Evaluation | 3 | 2018 | 1929 | 0.06 | Why? |
| Emergencies | 1 | 2018 | 4095 | 0.06 | Why? |
| Cross-Sectional Studies | 3 | 2020 | 53120 | 0.06 | Why? |
| Health Care Costs | 1 | 2011 | 1007 | 0.06 | Why? |
| Occupational Health | 1 | 2019 | 3965 | 0.06 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.06 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.06 | Why? |
| Follow-Up Studies | 2 | 2017 | 17020 | 0.06 | Why? |
| Socioeconomic Factors | 1 | 2019 | 8495 | 0.06 | Why? |
| Time Factors | 3 | 2020 | 31397 | 0.06 | Why? |
| Research Design | 1 | 2017 | 5830 | 0.05 | Why? |
| Hospital Mortality | 2 | 2021 | 22087 | 0.05 | Why? |
| Sensitivity and Specificity | 2 | 2021 | 22971 | 0.05 | Why? |
| Isoniazid | 1 | 2019 | 105 | 0.05 | Why? |
| Aged, 80 and over | 3 | 2021 | 88759 | 0.05 | Why? |
| Minority Groups | 2 | 2021 | 1631 | 0.05 | Why? |
| Self Disclosure | 1 | 2017 | 12 | 0.05 | Why? |
| Gross Domestic Product | 1 | 2019 | 134 | 0.04 | Why? |
| United Nations | 1 | 2021 | 367 | 0.04 | Why? |
| Coinfection | 1 | 2018 | 6820 | 0.04 | Why? |
| Prospective Studies | 2 | 2021 | 43301 | 0.04 | Why? |
| Stakeholder Participation | 1 | 2021 | 481 | 0.04 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2017 | 10649 | 0.04 | Why? |
| Myanmar | 1 | 2018 | 234 | 0.04 | Why? |
| Qualitative Research | 2 | 2021 | 4337 | 0.04 | Why? |
| Genes, Bacterial | 1 | 2017 | 207 | 0.04 | Why? |
| Immunocompromised Host | 1 | 2012 | 5150 | 0.04 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.04 | Why? |
| Logistic Models | 2 | 2021 | 9089 | 0.04 | Why? |
| Cost-Benefit Analysis | 2 | 2018 | 2259 | 0.04 | Why? |
| Genome, Bacterial | 1 | 2018 | 446 | 0.04 | Why? |
| Violence | 1 | 2020 | 534 | 0.03 | Why? |
| Economic Recession | 1 | 2019 | 453 | 0.03 | Why? |
| School Health Services | 1 | 2018 | 294 | 0.03 | Why? |
| Treatment Failure | 1 | 2019 | 2106 | 0.03 | Why? |
| Risk-Taking | 1 | 2017 | 508 | 0.03 | Why? |
| Unemployment | 1 | 2019 | 702 | 0.03 | Why? |
| Disease Notification | 1 | 2018 | 639 | 0.03 | Why? |
| Social Justice | 1 | 2020 | 706 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2021 | 11304 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2018 | 15909 | 0.03 | Why? |
| Demography | 1 | 2019 | 1660 | 0.03 | Why? |
| Bangladesh | 1 | 2018 | 1620 | 0.03 | Why? |
| Hepatitis B virus | 1 | 2019 | 882 | 0.03 | Why? |
| Observation | 1 | 2011 | 80 | 0.03 | Why? |
| Health Personnel | 3 | 2021 | 29646 | 0.03 | Why? |
| Recurrence | 1 | 2019 | 3675 | 0.02 | Why? |
| Microbial Sensitivity Tests | 1 | 2018 | 2886 | 0.02 | Why? |
| Disease Reservoirs | 1 | 2018 | 1672 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2017 | 2830 | 0.02 | Why? |
| Age Distribution | 1 | 2017 | 3567 | 0.02 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.02 | Why? |
| Odds Ratio | 1 | 2019 | 5861 | 0.02 | Why? |
| Prognosis | 2 | 2021 | 32490 | 0.02 | Why? |
| Homeless Persons | 1 | 2017 | 1171 | 0.02 | Why? |
| World Health Organization | 1 | 2019 | 4213 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2019 | 7268 | 0.02 | Why? |
| Self Report | 1 | 2017 | 3802 | 0.02 | Why? |
| Community-Acquired Infections | 1 | 2017 | 2328 | 0.02 | Why? |
| State Medicine | 1 | 2017 | 2847 | 0.02 | Why? |
| Antiviral Agents | 1 | 2017 | 41703 | 0.02 | Why? |
| Patient Admission | 1 | 2021 | 5250 | 0.02 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.02 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.01 | Why? |
| Societies, Medical | 1 | 2018 | 6907 | 0.01 | Why? |
| Surveys and Questionnaires | 2 | 2019 | 43792 | 0.01 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Infant, Newborn | 1 | 2017 | 23105 | 0.01 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 8811 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.01 | Why? |
| Referral and Consultation | 1 | 2011 | 4816 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2019 | 15421 | 0.01 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.01 | Why? |
| Comorbidity | 1 | 2018 | 34796 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.01 | Why? |
| Quality of Life | 1 | 2011 | 9820 | 0.01 | Why? |
| Animals | 1 | 2018 | 78931 | 0.01 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.01 | Why? |